VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index. The full press release is available at https://ibn.fm/jpXam.
This regulatory interaction is a critical milestone for VERAXA as it moves toward clinical trials. By receiving early feedback from the Paul-Ehrlich-Institute, the company can refine its development plan and address any regulatory concerns before initiating human studies. The BiTAC-TCE platform is designed to improve upon traditional T-cell engagers by requiring dual antigen recognition for activation, potentially reducing off-target toxicity and improving the therapeutic window.
The positive preclinical data presented at AACR 2026 reinforces the platform's potential. Selective targeting of cancer cells while sparing healthy cells could lead to fewer side effects and better patient outcomes. If these results translate into clinical success, VERAXA's BiTAC-TCE could become a significant advancement in cancer immunotherapy. The company's approach leverages its proprietary BiTAC technology, which is a registered trademark of VERAXA Biotech GmbH.
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
For more information and the latest news, visit the company's newsroom at https://ibn.fm/VRXA. The original release can be viewed on www.newmediawire.com.
